Founded in 2009 Symbiotix Biotherapies, Inc. is a pioneering microbiome company developing novel molecular therapeutics based on the human microbiome. Built on over two decades of groundbreaking research that has been elucidating how molecules produced by gut microbiota modulate the human immune system, the Company’s Scientific Co-Founders are three of the most distinguished thought leaders in the microbiome field:
• Prof. Dennis Kasper, M.D., the William Ellery Channing Professor of Medicine and Professor of Microbiology and Immunobiology at Harvard Medical School
• Prof. Sarkis Mazmanian, Ph.D., the Louis & Nelly Soux Professor of Microbiology in the Division of Biology & Biological Engineering at the California Institute of Technology
• Prof. Lloyd Kasper, M.D., Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College
“At Symbiotix Biotherapies, we are truly grateful and excited to announce the close of our institutional financing with Kairos Ventures. As we advance our lead Treg-modulating program towards clinical development as a first-in-class oral therapy for the safe and efficacious treatment of serious immune-mediated diseases, the support and funding by Kairos Ventures enables us to greatly accelerate our efforts to bring a safe and efficacious new treatment to patients.”
– Nader Yaghoubi, M.D., Ph.D., President and CEO of Symbiotix Biotherapies
As one of the earliest companies that launched the microbiome sector, Symbiotix has been steadily advancing first-in-class programs that modulate regulatory T cell (Treg) activity and are now described by over 100 scientific publications from the Company’s Scientific Co-Founders.
With the funding provided by Kairos, Symbiotix will further accelerate their programs and complete the necessary work in preparation for clinical trials. As part of the investment, Peter Alff joins the Symbiotix Board.
We are thrilled about our investment in Symbiotix and welcome them to the extended Kairos Ventures family!